Back to search
FDAFDA · Food and drugs·Recall number D-0727-2026

Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05

Published July 29, 2026 · Recall initiated: July 16, 2026

Summary

FDA records drug Class II recall D-0727-2026, published July 29, 2026 and initiated July 16, 2026. Recalling firm: Fresenius Kabi USA, LLC; Status: Ongoing; Reported quantity: 92,600 vials; Lot: Lot #: 6133436, Exp. Date 10/2028. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: Hair was found in products

What to do

Voluntary: Firm initiated · Letter

Get an email if NAROPIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NAROPIN
Manufacturer
Fresenius Kabi USA, LLC
Distributor
Nationwide within in the USA
UPC
0363323286033
Lot
Lot #: 6133436, Exp. Date 10/2028
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05 recalled?

Yes. FDA published recall D-0727-2026 on July 29, 2026. Reported hazard: Presence of Particulate Matter: Hair was found in products

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NAROPIN. UPC: 0363323286033.